 |
|
|
| |
Etravirine 200mg twice daily combined with atazanavir/ritonavir 300/100mg or 400/100mg once daily in treatment-experienced patients: primary 48-week efficacy and safety analysis of the TEACH trial
|
| |
| |
Reported by Jules Levin
IAS 2013 June 30-July 3 Kuala Lumpur
Catherine Orrell,1 Franco Felizarta,2 AndrŽ Nell,3 Thomas N Kakuda,4 Ludo Lavreys,5 Steven Nijs,5 Lotke Tambuyzer,5 Rodica Van Solingen-Ristea,4 Frank L Tomaka4
1Desmond Tutu HIV Foundation, UCT Medical School, Cape Town, South Africa; 2Private Practice, Bakersfield, CA, USA; 3Farmovs Parexel, Bloemfontein, South Africa; 4Janssen Research & Development LLC, Titusville, NJ, USA; 5Janssen Infectious Diseases BVBA, Beerse, Belgium
|
| |
|
|
|
|
|
